Immunosuppression therapy for idiopathic membranous nephropathy: systematic review with network meta-analysis.

ABSTRACT:

Background

Idiopathic membranous nephropathy is a common cause of nephrotic syndrome in adults. The Kidney Disease Improving Global Outcomes guidelines recommend rituximab or cyclophosphamide and steroids, or calcineurin inhibitor-based therapy. However, there have been few or no head-to-head comparisons of the relative efficacy and safety of different immunosuppression regimens. We conducted a network meta-analysis to evaluate the comparative efficacy and safety of available immunosuppression strategies compared to cyclophosphamide in adults with idiopathic membranous nephropathy.

Methods

We performed a systematic search of MEDLINE, Embase and CENTRAL for randomized controlled trials in the treatment of adults with idiopathic membranous nephropathy. The primary outcome was

SUBMITTER: Bose B 

PROVIDER: S-EPMC9107446 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature